Enzypep Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

  • Investors
  • 1

Enzypep General Information

Description

Developer of peptide ligation technology designed to offer the synthesis of oligopeptides. develops green, sustainable and cost-effective routes to synthesize pharmaceutical peptides and bioconjugates using its proprietary CEPS (Chemo Enzymatic Peptide Synthesis) and PECON (Protein Enzymatic CONjugation) toolbox, enabling companies to create pharmaceutical products with much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.

Contact Information

Website
www.enzypep.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Brightlands Campus
  • Building 93. Room 093.3.220, Urmonderbaan 22
  • 6167 RD Geleen
  • Netherlands
+31 046
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Vertical(s)
Corporate Office
  • Brightlands Campus
  • Building 93. Room 093.3.220, Urmonderbaan 22
  • 6167 RD Geleen
  • Netherlands
+31 046

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enzypep Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Jan-2019 Completed Out of Business
2. Early Stage VC 01-Jan-2015 Completed Startup
1. Early Stage VC 01-Jun-2012 Completed Startup
To view Enzypep’s complete valuation and funding history, request access »

Enzypep Patents

Enzypep Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024208687-A1 Method for the preparation of lactulose Inactive 06-Apr-2023
WO-2024133313-A1 Thermostable subtilisin variants and their use Inactive 19-Dec-2022
WO-2019170918-A1 Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1 Inactive 09-Mar-2018
WO-2019170895-A1 Chemo-enzymatic synthesis of semaglutide, liraglutide and glp-1 Inactive 09-Mar-2018
CA-3060389-A1 Subtilisin variants having a mutation in the s2 or s2' pocket Active 19-May-2017 C12N9/52
To view Enzypep’s complete patent history, request access »

Enzypep Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enzypep Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Rijksdienst voor Ondernemend Nederland Government Minority
To view Enzypep’s complete investors history, request access »

Enzypep Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
EnzyTag Nuth, Netherlands 2018

Enzypep FAQs

  • When was Enzypep founded?

    Enzypep was founded in 2012.

  • Where is Enzypep headquartered?

    Enzypep is headquartered in Geleen, Netherlands.

  • What is the size of Enzypep?

    Enzypep has 4 total employees.

  • What industry is Enzypep in?

    Enzypep’s primary industry is Biotechnology.

  • Is Enzypep a private or public company?

    Enzypep is a Private company.

  • What is Enzypep’s current revenue?

    The current revenue for Enzypep is .

  • How much funding has Enzypep raised over time?

    Enzypep has raised $4.91M.

  • Who are Enzypep’s investors?

    Rijksdienst voor Ondernemend Nederland has invested in Enzypep.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process